PTC Therapeutics

PTCT

Market cap $5.44B

WARREN, N.J. , Oct. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.

On Saturday, BioMarin Pharmaceutical Inc. BMRN released new Phase 3 PEGASUS study results on Saturday.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:35 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Hi, good morning, everybody. I'm Kristen Kluska, one of the biotech analysts at Cantor.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Thanks, everyone, for joining us.

Shares in PTC Therapeutics (PTCT 4.43%) surged by 17.5% in the week to Friday morning, as the market digested management's upbeat presentation at the Cantor Global Healthcare Conference on Wednesday.

PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030.

WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 2025 Wednesday, Sept.

Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votoplam for treatment of HD patients, with up to $1.9 billion in milestone payments possible.

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s PTCT New Drug Application (NDA) for vatiquinone for Friedreich's ataxia.